TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04533438

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RhinAer Stylus
Description: The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
Study: NCT02260921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera°

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Study: NCT02520076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin
Description: Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~* Pre-transplant Day -1~* Post-transplant Day 3~* Post-transplant Day 7~* Post-transplant Day 14
Study: NCT02502643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK-432 pleurodesis
Description: 1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline pleurodesis
Description: Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
Study: NCT01490229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: os, 10 mg, once daily, 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceuticals
Description: os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
Study: NCT00653172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXL103
Description: 600mg orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparator
Description: comparator twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXL103
Description: 500mg orally twice daily
Study: NCT03601715

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coplanar
Description: The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contraplanar
Description: The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
Study: NCT02516215

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT00438113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Blood Pressure control
Description: Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
Study: NCT04208698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-102 Dose 1
Description: Deuterated domperidone (deudomperidone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-102 Dose 2
Description: Deuterated domperidone (deudomperidone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CIN-102
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CIN-102
Description: Placebo
Study: NCT03041545

Intervention type: DEVICE
Intervention: Fitbit
Description: Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
Study: NCT01240447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: racotumomab
Description: Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.

Intervention type: OTHER
Group type: OTHER
Intervention: Best support treatment
Description: Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
Study: NCT02418026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: Conversational hypnotic induction and therapeutic suggestions
Study: NCT00766480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy
Study: NCT03128892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index - RD Lite Sensors
Study: NCT02749981

Intervention type: PROCEDURE
Intervention: blood and tissue sampling
Study: NCT04253145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM 01183
Description: Lyophilisate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Concentrate for solution for infusion
Study: NCT01524692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258)
Description: 500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
Study: NCT00379574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib:~For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.~For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 750mg/m2 day 1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: doxorubicin 50 mg/m2 day 1, every 2 weeks
Study: NCT00025259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT00379574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: prednisolone 100 mg days 1-5, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenograstim
Description: Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
Study: NCT01784640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor AUY922
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00326456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 30 mg/m2 gieven intravenously on day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5 intravenously on day 1 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC 5 intravenously on day 1 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m2 intravenously on day 1 every 3 weeks
Study: NCT00268957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (Renvela®)
Description: sevelamer carbonate powder dosed once per day with largest meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer hydrochloride (Renagel®)
Description: Sevelamer hydrochloride tablets dosed three times a day with meals
Study: NCT01650623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait training executive functions tasks
Description: The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training alone
Description: The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
Study: NCT02978261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1001
Description: PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
Study: NCT01239654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent implantation
Description: implantation of everolimus-eluting stent vs zotarolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent implantation
Description: implantation of everolimus-eluting stent vs zotarolimus-eluting stent
Study: NCT02281461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Male circumcision using a non-surgical device
Description: Male Circumcision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Male circumcision using a non-surgical device
Description: Male Circumcision
Study: NCT02317068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBR

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DD
Study: NCT01488682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck dissection with Harmonic scalpel
Description: The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neck dissection with conventional hand-tie ligation
Description: electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
Study: NCT00194064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Study: NCT02670564

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics
Description: Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics
Description: Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics
Description: Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Busulfan plasma level measurements
Description: Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).~Blood sampling:~-\>For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion~-\>For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.~For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:~-\> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below
Study: NCT03601715

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Longitudinal
Description: The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
Study: NCT01743235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study: NCT02472418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Dose A (treatment A)
Description: DFN-15 Dose A administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Dose B (treatment B)
Description: DFN-15 Dose B administered

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (treatment C)
Description: Placebo administered
Study: NCT01655121

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein high fiber diet
Description: A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein high fiber diet
Description: A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months.
Study: NCT00350272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elvucitabine
Description: Elvucitabine 10 mg orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine 300 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir open-label 300 mg orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir open-label 300 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenze open-label 600 mg orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenze open-label 600 mg orally daily
Study: NCT03193814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Apatinib
Description: chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
Study: NCT00532025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
Study: NCT01832623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exploration of Vitamin D roles
Description: * Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~* Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside
Study: NCT01703689

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audit and Feedback
Description: Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooperative Work
Description: Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
Study: NCT02743871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given one dose of PF-06817024 intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06817024
Description: Subjects will be given one dose of PF-06817024 intravenously
Study: NCT03956277

Intervention type: DEVICE
Intervention: PUG
Description: This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
Study: NCT01953549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical fitness training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Study: NCT04627623

Intervention type: DIAGNOSTIC_TEST
Intervention: IgM and IgG antibodies assay
Description: 5 ml venous blood sample collection to assay IgM and IgM against COVID19
Study: NCT01939002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen
Study: NCT01165112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies